Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst
1. Lucid Diagnostics is likely to gain Medicare reimbursement for EsoGuard testing. 2. Analyst Mike Matson maintains a Buy rating with a $3 price target. 3. Over 25,000 EsoGuard tests completed; reimbursement expected in early 2025. 4. Clinical studies show nearly 100% concordance and negative predictive value. 5. Recent stock offering caused a 6.80% decline in stock price.